Source: CodeBlue

A Sungai Buloh Hospital clinician also described the controversial antimalarial drug, hydroxychloroquine, as an anchor during the peak of the Covid-19 crisis in Malaysia.

Dr Suresh Kumar, infectious diseases clinician

KUALA LUMPUR, June 17 — Malaysia’s Covid-19 team learned early during the outbreak that some patients were deteriorating not directly from the coronavirus, but from resulting inflammation, a Sungai Buloh Hospital clinician said.

Dr Suresh Kumar, an infectious diseases clinician at the main Covid-19 designated hospital in Malaysia, detailed how Malaysian Covid-19 clinicians learned early on that inflammation was the major culprit in the cause of death associated with Covid-19 infection. So treatment for these patients were modified accordingly to incorporate the use of anti-inflammatories, which subsequently prevented intensive care unit (ICU) admissions.

“Quite early on we learned to use anti-inflammatory agents in selected cases that were undergoing deteriorating, We were able to prevent the ICU admissions by doing that.

Dr Suresh Kumar, infectious diseases clinician

“If we had had the disease a lot later down the track we could’ve learned a lot more from the Italians and the Chinese and we learned early that some of these patients were deteriorating not because of the virus (directly) but because of the inflammation (caused by the virus),” Dr Kumar told Fifa Rahman for her report on the Malaysian response to Covid-19 that was written in collaboration with the Drugs for Neglected Diseases initiative (DNDi), a Geneva-based research and development non-profit.

The unknowns that came along with the novel coronavirus in deciding the right treatment for Covid-19 patients proved to be a great challenge for physicians, especially during the early days of the outbreak, as pointed out by Dr Kumar in his testimonial for DNDi’s report on the Malaysian response to Covid-19.

“We needed to work on what was available at that particular juncture. At that particular juncture — albeit there not being high quality evidence — we learned from Chinese experience that hydroxychloroquine works, we prescribed hydroxychloroquine early for all symptomatic patients,” he said.

He further emphasised that high-dose hydroxychloroquine was not used by Malaysian clinicians to treat Covid-19 patients, citing Brazil sources who claimed that high doses of the anti-malarial drug to be harmful as it can negatively affect the heart.

Dr Suresh Kumar, infectious diseases clinician

He also added that it was not part of Malaysian practice to use hydroxychloroquine with azithromycin, an antibiotic known to add to the cardiac side effects associated with the anti-malarial drug.

“We did use it not with azithromycin because we were worried about the cardiac problems. We monitored with ECG and we didn’t find anything major. It became our anchor when many patients became sick,” he explained, adding that other combinations of HIV drugs such as Kaletra and interferon were also used as experimental treatment for the coronavirus.

Recent upstir on the safe use of hydroxychloroquine to treat Covid-19 patients does not only focus on its benefit versus risk issue, but also on whether the anti-malarial drug works at all as an effective Covid-19 treatment. Main stream media, WHO and the U.S. FDA seem to be ignorant of any positive study that has been performed world wide.


Study – Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world (19,270 patients – is effective)

YALE: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis (HCQ – AZ)

FDA enables use of HCQ in a weird round about way – by revoking EUA. Says they never restricted it.


Indonesia Claims Five Drug Combos, including HCQ, Reduce Novel Coronavirus

Study: Strategy – HCQ + AZ treats mild COVID-19 to reduce hospital admissions and complications.

Decreased mortality and hospital – Doxycycline and Hydroxychloroquine for High-Risk COVID-19 Patients: Case Series of 54 Patients in Long-Term Care

WHO told governments to stop using HCQ based on suspect data from tiny US company. Trials now continue with new confidence.

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »